Northwest Biotherapeutics (NWBO) Payables (2010 - 2026)

Northwest Biotherapeutics' Payables history runs 17 years deep, the most recent figure standing at $43.2 million for Q1 2026.

• On a quarterly basis, Payables rose 98.46% year-over-year to $43.2 million in Q1 2026; TTM through Mar 2026 was $43.2 million, a 98.46% increase from a year earlier, with the FY2025 full-year figure at $40.3 million, up 109.94% from the prior year.
• Payables grew to $43.2 million in Q1 2026 per NWBO's latest filing, from $40.3 million in the prior quarter.
• Across five years, Payables topped out at $106.3 million in Q1 2022 and bottomed at $11.2 million in Q4 2023.
• The 5-year median for Payables is $25.5 million (2024), against an average of $35.9 million.
• Across the five-year window, Payables surged 372.24% in 2022 and tumbled 87.46% in 2023, its largest moves.
• Year by year, Payables stood at $26.1 million in 2022, then sank by 57.12% to $11.2 million in 2023, then soared by 71.51% to $19.2 million in 2024, then jumped by 109.94% to $40.3 million in 2025, then grew by 7.32% to $43.2 million in 2026.
• Per Business Quant, the three latest NWBO Payables figures stand at $43.2 million (Q1 2026), $40.3 million (Q4 2025), and $40.4 million (Q3 2025).